97,600 Shares in Kenvue Inc. $KVUE Purchased by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System acquired a new position in shares of Kenvue Inc. (NYSE:KVUE) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 97,600 shares of the company’s stock, valued at approximately $1,683,000.

A number of other large investors have also recently bought and sold shares of KVUE. Physician Wealth Advisors Inc. increased its position in Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after acquiring an additional 618 shares during the period. Elyxium Wealth LLC bought a new stake in shares of Kenvue during the fourth quarter worth $26,000. MV Capital Management Inc. bought a new stake in shares of Kenvue during the fourth quarter valued at approximately $28,000. Reflection Asset Management acquired a new stake in Kenvue in the fourth quarter worth about $32,000. Finally, SBI Securities Co. Ltd. lifted its stake in Kenvue by 82.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after buying an additional 1,027 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Insider Activity at Kenvue

In other news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 1.59% of the company’s stock.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $19.33 on Thursday. The firm has a market cap of $37.11 billion, a PE ratio of 22.74, a price-to-earnings-growth ratio of 1.45 and a beta of 0.54. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $22.87. The firm’s fifty day moving average is $17.76 and its 200-day moving average is $17.68. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The firm had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. During the same period in the previous year, the business earned $0.24 EPS. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. Sell-side analysts predict that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were paid a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.3%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s payout ratio is currently 97.65%.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Zacks Research raised Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 8th. Citigroup lowered their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 15th. UBS Group reduced their price target on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 7th. Barclays cut their target price on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 14th. Finally, Argus upgraded Kenvue to a “hold” rating in a research note on Friday, March 6th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus target price of $19.33.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.